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Purpose: To determine the effect of a sustained-release dexamethasone implant (Ozurdex®) on wound healing after
glaucoma filtration surgery in a rabbit model.
Methods: Twelve New Zealand white rabbits were divided into three groups: filtration surgery with intraoperative
subconjunctival implantation of Ozurdex® (n=6), filtration surgery with intraoperative topical application of mitomycin-
C (MMC; n=6), and filtration surgery with intraoperative topical application of balanced salt solution (BSS; n=12). A
standard scale was used to grade bleb vascularity at three and six weeks after the initial operation. Bleb survival was also
recorded for comparison between the three groups. Histologic analysis was performed with attention to cellularity and
collagen deposition.
Results: MMC-treated blebs demonstrated decreased numbers of goblet cells compared to all other groups. Blebs treated
with Ozurdex® maintained a near normal number of goblet cells with modest collagen deposition. The control eyes treated
with only BSS had significant collagen deposition and increased cellularity compared to both the Ozurdex® and MMC
groups. Bleb vascularity was not significantly different among groups at the three and six week post-operative evaluations.
MMC-treated and Ozurdex®-treated blebs had significantly prolonged bleb survival compared to blebs treated with only
BSS. In addition, MMC-treated blebs had significantly longer survival compared to Ozurdex®-treated blebs.
Conclusions: The results of this study support the utility of extended-release dexamethasone (Ozurdex®) as a wound
modulating agent in a rabbit model of filtration surgery. Further animal and human studies are needed to better characterize
a possible role for Ozurdex® in filtration surgery.
Modern glaucoma filtration surgery requires construction
of a wound that strikes a balance between under- and over-
filtration to achieve adequate long-term control of intraocular
pressure. The natural healing processes of the eye favor scar
formation  after  incisional  surgery,  which  can  limit  bleb
function. Modulation of the post-operative healing response
after guarded filtration surgery for glaucoma has historically
relied  on  the  antifibrotics  mitomycin-C  (MMC)  and  5-
fluorouracil (5-FU). These agents have been shown to be
effective and their use is supported by large clinical trials and
decades  of  use  in  human  subjects  [1-7].  Newer  agents
targeting  specific  growth  factors,  such  as  anti-vascular
endothelial growth factors (anti-VEGF) and anti-transforming
growth factor β2 (anti-TGF-β2), have also recently been under
investigation [8-11].
Steroids, in particular glucocorticoids, have widespread
applications in ophthalmology due to their anti-inflammatory
properties. Glucocorticoids act in a nonspecific fashion to
blunt immune and inflammatory responses and can influence
several components of the wound healing pathway [5,12].
Ultimately,  glucocorticoids  modulate  wound  healing  by
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decreasing  vascular  permeability  leading  to  decreased
leukocyte migration and activity in damaged tissues [5]. Use
of topical corticosteroids after glaucoma filtration surgery is
considered standard of care and has been shown to augment
surgical success [13].
Ozurdex®  (Allergan,  Irvine,  CA)  is  a  polymer-based
sustained-release intravitreal drug delivery system containing
0.7  mg  of  the  glucocorticoid  dexamethasone.  Given  the
known wound modulation properties of glucocorticoids, we
hypothesized that Ozurdex® would have a measurable and
sustained  effect  on  bleb  morphology  and  histology  after
filtration surgery. This study compares outcomes in a rabbit
model  of  filtration  surgery  using  MMC,  Ozurdex®,  or
balanced salt solution (BSS) control.
METHODS
Study design: All procedures were performed in accordance
with  The  Association  for  Research  in  Vision  and
Ophthalmology (ARVO) Statement for the Use of Animals in
Ophthalmic and Vision Research. The eyes of twelve New
Zealand  white  rabbits  were  divided  into  three  groups:
filtration  surgery  with  intraoperative  subconjunctival
implantation  of  Ozurdex®  (n=6),  filtration  surgery  with
intraoperative topical application of MMC (n=6) and filtration
surgery with intraoperative topical application of BSS (n=12).
The number of rabbits was chosen based on our experience in
previous studies with a similar animal model. No data were
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714Figure  1.  MMC-treated  tissue  was  noted  to  have  less  collagen
deposition  (asterisk)  with  Masson  Trichrome  stain  compared  to
Ozurdex®- or BSS-treated eyes as well as loss of normal distribution
of goblet cells in all sections (10× magnification).
available to calculate sample sizes since the medication of
interest has not been studied in this fashion to our knowledge.
All rabbits underwent glaucoma filtration surgery in the right
eye  performed  by  a  single  surgeon  (M.Y.K.)  using  an
established technique described by Cordeiro and colleagues
[8]. The left eye of each rabbit acted as the control (n=12) and
underwent  filtration  surgery  without  the  use  of  an
intraoperative wound-modulating agent.
Glaucoma  filtering  surgery  technique:  Each  rabbit  was
anesthetized using a combination of intramuscular ketamine
and xylazine (ketamine 40 mg/kg; xylazine 20 mg/kg) and
topical  anesthesia  (2%  lidocaine  gel)  before  initiation  of
Figure 2. A normal number of conjunctival goblet cells (arrows) per
high power field with Hematoxylin and Eosin stain was noted in
sections from the Ozurdex®-treated eyes (40× magnification).
TABLE 1. GRADING OF CENTRAL BLEB VASCULARITY.
Central bleb vascularity score Central bleb vascularity
0 Avascularity (>50% avascularity)
1 Reduced vascularity (<50% avascularity)
2 Normal vascularity
3 Increased vascularity (<50% increased vascularity)
4 Hypervascularity (>50% increased vascularity)
TABLE 2. BLEB HISTOLOGY.
Group Collagen deposition (Masson
trichrome)
Cellularity (H&E) Mean goblet cell number (SD)
Mitomycin C ± ± 1.33 (0.82)
Ozurdex® ++ + 6.83 (0.75)
BSS control +++ +++ 7.33 (1.03)
        -=absent;  ±=weakly  present;  +,++,+++=present.  H&E=Hematoxylin  and  Eosin.  SD=Standard  Deviation.  p<0.001  for  the
        comparison of goblet cell number in eyes treated with MMC versus those treated with Ozurdex® or BSS. p=0.31 for the
        comparison of goblet cell number in eyes treated with Ozurdex® versus those treated with BSS.
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715surgery.  A  fornix-based  conjunctival  dissection  was
completed and a 23-gauge needle was used to create a scleral
tunnel one millimeter posterior to the limbus for insertion of
a  22-gauge  cannula  (Insyte®;  Becton  Dickinson  Vascular
Access, Sandy, UT) into the anterior chamber. The cannula
was inserted such that the distal end crossed the pupillary
margin to avoid tube-iris capture. The tube was then secured
to  the  scleral  bed  with  10–0  nylon  suture  (Ethicon  Inc.,
Somerville, NJ) and efflux of fluid into the subconjunctival
space was confirmed. In the Ozurdex® group, the medication
pellet  was  injected  into  a  sterile  plastic  cup  using  the
manufacturer’s injecting system. The pellet was then grasped
with 0.12 forceps and placed immediately posterior to the
proximal end of the implanted cannula. In the MMC group,
two  3×3  mm  partial-thickness  Weck-cel®  spears  (Alcon
Surgical, Fort Worth, TX) soaked in 0.4 mg/ml MMC solution
were placed over the scleral bed for 5 min before insertion of
the 22-gauge cannula. The scleral bed was then irrigated with
40  ml  of  BSS  after  removing  the  soaked  spears  and  the
surgical procedure was completed. The left eye of each animal
(in both groups) underwent the exact procedure as noted above
for the MMC-treated eyes except the Weck-cel® spears were
soaked  in  BSS  instead  of  MMC.  In  all  eyes,  topical
moxifloxacin 0.5% solution (Vigamox®; Alcon, Fort Worth,
TX)  and  prednisolone  acetate  1%  suspension  (Predforte®;
Allergan, Irvine, CA) were each instilled four times per day
for seven days following surgery.
Post-operative  evaluation:  A  daily  handheld  slit  lamp
examination  of  the  operated  eyes  following  surgery  was
conducted to document any changes at the surgical site as well
as to complete bleb vascularity assessments. Anterior segment
photographs were obtained weekly for the duration of the
Figure 3. Histologic analysis of bleb tissue revealed less collagen
deposition  with  Masson  Trichrome  stain  compared  to  the  BSS
control as well as a thin capsule (white arrow) at the location of the
Ozurdex® implant (10× magnification).
study in each eye. These daily examinations and photographs
were  evaluated  for  the  presence  of  implant  migration  or
extrusion.  A  single,  masked  independent  investigator
objectively  graded  each  bleb  for  survival  and  vascularity
based on slit lamp photography. The primary outcome metric
was bleb histology and bleb survival, which was defined as
the presence of an elevated subconjunctival fluid pocket at the
surgical site. Central bleb vascularity was also graded from
photographs taken at three and six weeks post-operatively
using a standard scale as noted in Table 1. Intraocular pressure
was not collected as an endpoint since our specific metric of
interest involved histologic differences between groups.
Histology: All animals were euthanized at the end of the six-
week study. All eyes were then enucleated and immediately
immersed in a mixture of 4% paraformaldehyde and 2.5%
neutral  buffered  formalin  for  24  h.  The  globes  were
dehydrated, embedded in paraffin and sent for microtome
sectioning and staining (Hematoxylin and Eosin and Masson
Trichrome;  Sigma,  St.  Louis,  MO).  A  modified  semi-
quantitative grading system to assess cellularity and collagen
deposition was used to compare findings between the three
Figure 4. Exuberant collagen deposition with Masson Trichrome
stain was noted in all evaluated sections from BSS-treated controls
(10× magnification).
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716groups (Table 2) [14]. Goblet cell number was calculated
using the average cell number per high-powered field from
six consecutive central bleb cross-sections of each specimen
(Table 2). A prior study has established that normal rabbit
conjunctiva typically has about seven goblet cells per high-
powered field [15]. A masked evaluation was then performed
on all samples. Statistical analysis using one-way analysis of
variance (ANOVA) test was completed for all data sets. A p-
value <0.05 was considered statistically significant.
RESULTS
Blebs treated with MMC demonstrated a decrease in number
of goblet cells along with minimal collagen deposition and
cellularity compared to all other eyes (p<0.001; Figure 1 and
Table 2). In contrast, Ozurdex®-treated blebs maintained a
normal  number  of  goblet  cells  compared  to  BSS  control
(p=0.31;  Figure  2)  with  modest  collagen  deposition  and
increased cellularity as shown in Table 2. There was a thin
capsule surrounding the location of all Ozurdex® implants but
no evidence of foreign body reaction (Figure 3). The BSS-
treated eyes had significant collagen deposition and increased
cellularity compared to both the Ozurdex® and MMC groups
(Figure 4 and Table 2). In addition, the BSS-treated eyes
maintained  a  normal  number  of  goblet  cells  compared  to
previously  published  literature  [15].  Bleb  vascularity  was
similar between groups at both three and six weeks follow up
(p>0.05 for all comparisons; Table 3).
There were no documented cases of implant extrusion,
endophthalmitis,  corneal  epithelial  toxicity,  or  persistent
anterior chamber inflammation in all treated eyes.
DISCUSSION
Our  findings  support  the  utility  of  extended-release
dexamethasone for wound modulation in a rabbit model of
filtration surgery. The results of this study documented that
use of Ozurdex® resulted in improved bleb survival compared
to BSS control and favorable bleb histology compared to the
MMC group. Ozurdex® is currently approved by the United
States Food and Drug Administration for the treatment of
macular edema following retinal vein occlusion as well as
noninfectious  posterior  uveitis.  In  the  current  study,
Ozurdex®-treated  eyes  demonstrated  favorable  bleb
morphology and histology. The stable density of goblet cells
combined with modest fibroblast proliferation and collagen
deposition suggest that the use of sustained-release steroid
may allow for the formation of thicker, more stable blebs. It
remains unclear what the impact might be on the degree of
intraocular pressure lowering in this scenario. The Ozurdex®
and  MMC  groups  both  demonstrated  a  significantly
prolonged  bleb  survival  time  compared  to  controls.  The
significant  difference  between  the  Ozurdex®  and  MMC
groups in bleb survival might be predictable, but the increased
survival of Ozurdex® blebs over that of BSS-treated blebs
suggests potential for sustained-release dexamethasone for
wound modulation after filtration surgery.
Table 4 lists post-operative bleb survival for each of the
three  groups.  MMC-treated  and  Ozurdex®-treated  blebs
demonstrated a statistically significant increase in duration of
post-operative bleb survival compared to the BSS control
group  (p<0.001  for  both  comparisons).  There  was  also  a
significant  difference  in  bleb  survival  in  the  comparison
between the MMC and Ozurdex® groups in favor of MMC-
treated eyes (p=0.001).
The process of wound healing is complex and involves
multiple  vascular  and  cellular  pathways  with  cross
interactions that are not fully understood [5]. While modern
glaucoma filtration surgery with concurrent use of 5-FU or
MMC  is  a  well  recognized  and  successful  technique,  the
opportunity  exists  to  explore  the  use  of  other  agents  to
TABLE 3. MEAN POST-OPERATIVE VASCULARITY OF ALL GROUPS AFTER THREE AND SIX WEEKS OF FOLLOW-UP.
Group Three weeks (SD) Six weeks (SD)
Mitomycin-C (n=6) 1.17 (1.47) 1.50 (1.64)
Ozurdex® (n=6) 1.83 (1.47) 2.00 (1.67)
Control (n=12) 2.08 (1.16) 2.50 (1.38)
          SD=Standard Deviation. p>0.05 for comparison of bleb vascularity between all groups.
TABLE 4. POST-OPERATIVE BLEB SURVIVAL.
Group Bleb Survival – Days (SD) Range
Mitomycin-C (n=6) 39.33 (3.56) 33–42
Ozurdex® (n=6) 30.17 (3.43) 26–35
Control (n=12) 11.17 (3.27) 5–16
        SD=Standard Deviation. p<0.001 for comparison of bleb survival in eyes treated with BSS versus those treated with Ozurdex® or
        MMC. p=0.001 for comparison of bleb survival in eyes treated with Ozurdex® versus those treated with MMC (in favor of
        MMC-treated eyes).
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717augment surgical success while at the same time decreasing
the risk of post-operative complications. Mitomycin-C acts as
an antiproliferative agent via DNA cross-linking, which in
turn inhibits both DNA replication and protein synthesis [5].
With regards to glaucoma filtration surgery, these inhibitory
effects decrease fibroblast proliferation leading to decreased
scar  formation  and  improved  bleb  function  and  survival
[16-18]. Use of MMC, however, does increase the risk of
postoperative bleb leak, hypotony, and endophthalmitis [5,
19,20]. Due to the multifactorial nature of wound healing, it
is  likely  that  multiple  agents,  used  either  concurrently  or
sequentially, may be needed to achieve the aforementioned
goals  [21].  The  exact  combination,  dose,  and  route  of
administration of treatments that produces the best surgical
outcome with minimal side effects is not yet determined and
is a worthwhile area of research.
The efficacy of topical post-operative medications such
as corticosteroids is by nature dependent on a patient’s ability
to  properly  instill  the  medications  while  following  the
appropriate timeline for their use. Intraoperative retrobulbar
triamcinolone  acetonide  has  been  shown  to  augment  the
success of trabeculectomy with MMC, but the duration of
action is short and instillation is difficult due to reflux of fluid
from the surgical site [22]. Others have reported success with
injection of triamcinolone acetonide directly into the bleb at
the conclusion of surgery [23].
This animal model provides insight regarding the ideal
regimen for wound modulation following filtration surgery
but does have significant limitations. The size of the treatment
groups in this pilot study was small, although in line with
previously published studies investigating bleb characteristics
in rabbits, and it remains to be seen what effect sustained-
release corticosteroids may have on long-term bleb function
and survival using a larger number of animals. It is also noted
that  results  from  an  animal  study  may  not  be  directly
applicable  to  human  patients.  The  rabbit  is,  however,  an
established model for the evaluation of novel techniques in
glaucoma filtration surgery [24-26].
A  sustained-release  corticosteroid  implant  such  as
Ozurdex® does have many possible advantages. However, its
use for filtration surgery is limited due to its original design
for intravitreal use. Enhancements could include a wider and
flatter profile that would lessen the chance of conjunctival
erosion  and  increase  the  amount  of  tissue  exposed  to
medication as well as tailoring the dose and time release of
active ingredient specifically for wound modulation. Unlike
the use of MMC, it is not possible to vary the concentration,
treatment area, or duration of exposure to Ozurdex®. Cost and
availability of Ozurdex® may also limit its use in resource-
poor treatment areas. As always, the ophthalmic side effects
of corticosteroids, including cataract formation and increased
intraocular pressure, need to be carefully weighed against the
benefits of therapy.
The results of this preliminary rabbit study suggest a role
for Ozurdex® as a wound modulator after traditional glaucoma
filtration  surgery.  Compared  to  blebs  treated  with  MMC,
Ozurdex®-treated blebs were thicker with less disruption of
baseline  cellular  architecture.  Use  of  Ozurdex®  could
potentially allow for combination therapy with MMC or 5-
FU.  For  example,  using  a  lower  dose  of  MMC  with
Ozurdex® might lead to improved wound modulation while
also  decreasing  the  incidence  of  MMC-associated
complications. The use of a sustained drug delivery system
may also allow for more consistent and reproducible results
compared to the variability of compounding pharmacy MMC
doses as well as the variable techniques used by surgeons
when applying MMC intra-operatively. Further studies are
needed to better characterize and expand on these preliminary
results and human studies would be needed to fully understand
the surgical and clinical utility of this wound modulation
approach.
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